Panitumumab-Irdye800

Meningioma

Eben RosenthalEarly Phase 1Active

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 24/ 100
Competitive Position: 89/ 100

Competitive context

10 Active assets in the Meningioma cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide Essen Biotech	Phase 2	B
Fludarabine Essen Biotech	Phase 2	B
Nivolumab National Cancer Institute (NCI)	Phase 2	B
Anti-Ny Eso-1 Mtcr Pbl National Cancer Institute (NCI)	Phase 2	B
Rvp-001 Reveal Pharmaceuticals Inc.	Phase 2	B

View all 19 →

Same molecule, other indications

Panitumumab-Irdye800 is also rated in:

pancreatic adenocarcinomaDormant

CC

Indicative ·

43 / 100

acoustic neuromaDormant

C

Indicative ·

39 / 100

brain cancerDormant

C

Indicative ·

38 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.